Understand the source comparison
Peptides for Neuropathic Pain Protocol — Evidence Comparison
Before selecting a peptide protocol, understanding the evidence base and administration requirements for each compound is critical. BPC-157 VEGF/BDNF upregulation, TNF- suppression, Schwann cell proliferation Rodent models: 62% reduction in mechanical allodyn
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understanding the evidence base and administration requirements for each compound is critical.
- BPC-157
- VEGF/BDNF upregulation, TNF-α suppression, Schwann cell proliferation
- Rodent models: 62% reduction in mechanical allodynia (2024 Neuropeptides). Human data limited to case reports.
- 200–500 mcg daily (human equivalent dose)
- Subcutaneous injection, local or systemic
- Minimal reported AEs in animal studies. No FDA approval for human use.
- TB-500
- Actin polymerisation, MMP modulation, axonal navigation through scar tissue
- Diabetic neuropathy models: 38% reduction in mechanical hypersensitivity (Regenerative Medicine, 2019). No Phase III human trials.
- 2.5–5 mg twice weekly
- Subcutaneous or intramuscular injection
- Well-tolerated in regenerative medicine protocols. No serious AEs reported.
- Cerebrolysin
- NGF-like neurotrophic activity, neuroplasticity enhancement
- Phase II diabetic neuropathy trial: 42% VAS pain reduction at 12 weeks (2021). FDA-approved in some countries for stroke recovery.
- 10–30 mL IV infusion over 10–20 days
- Intravenous infusion only
- Dizziness, headache in 8–12% of subjects. Rare hypersensitivity reactions.
- Dihexa
- HGF/c-Met pathway activation, synaptic density increase
- Cognitive enhancement models only. No neuropathic pain-specific trials published.
- 1–5 mg orally (investigational)
- Oral administration
- Limited human safety data. CNS penetration unverified in peripheral neuropathy.